

Supplementary material _1

Journal name: The Romanian Journal of Laboratory Medicine

Article title: High DNAJA4 expression correlates with poor survival outcomes in breast cancer

TMA Name BC081116b

Description Breast cancer tissue array with adjacent breast tissue as control, including pathology grade, TNM, clinical stage and IHC markers (ER, PR and Her-2), 110 cases/ 110 cores, replacing BC081116a

Panel Breast carcinoma tissue microarray with adjacent breast tissue, containing 100 cases of breast invasive ductal carcinoma and 10 cases of adjacent breast tissue, single core per case

Cases 110

Cores 110

Diameter 5

Rows 11

Columns 10

- One sample (Position: D6) is overlap with the cases of TMA (BR486; Positions: A8, B8, C8)

Position	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Tissue ID.	ER	PR	HER2
A1	1	60	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg050265	+++	+++	0
A2	2	49	F	Breast	Invasive ductal carcinoma	T3N1M0	1	IIIA	malignant	Fmg050281	-	-	1+
A3	3	67	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg050259	-	-	3+
A4	4	58	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg050233	+++	-	0
A5	5	38	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg020189	-	-	0
A6	6	52	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg020147	-	-	3+
A7	7	64	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg010825	*	*	*
A8	8	59	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	Fmg010906	-	-	0
A9	9	52	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	Fmg010838	+++	+	0
A10	10	70	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg020312	+	-	0
B1	11	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010868	+++	+++	0
B2	12	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg050278	+++	+	0
B3	13	50	F	Breast	Invasive ductal carcinoma	T3N2M0	2	IIIA	malignant	Fmg020093	+++	+	1+
B4	14	43	F	Breast	Invasive ductal carcinoma	T1cN0M0	-	I	malignant	Fmg010839	+++	+++	0
B5	15	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020204	+++	++	3+
B6	16	74	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020170	+++	++	0
B7	17	71	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg050754	-	-	0
B8	18	42	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	malignant	Fmg050739	-	-	1+
B9	19	32	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIB	malignant	Fmg050755	++	-	3+
B10	20	87	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg050794	-	-	1+
C1	21	50	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg020182	+	+	1+
C2	22	46	F	Breast	Invasive ductal carcinoma	T2N0M0	-	IIA	malignant	Fmg020168	-	-	3+
C3	23	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020012	-	-	3+
C4	24	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020183	-	-	0
C5	25	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020151	+++	+++	0
C6	26	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010769	-	-	3+
C7	27	45	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIB	malignant	Fmg010767	+++	+++	0
C8	28	95	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	Fmg020192	+++	+	2+
C9	29	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020141	-	-	2+
C10	30	53	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	malignant	Fmg020327	-	-	0
D1	31	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010932	+++	++	0
D2	32	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010834	+++	-	1+
D3	33	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010917	++	+++	0
D4	34	45	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg020179	+++	+	3+
D5	35	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020140	++	+++	0
D6	36	34	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIB	malignant	Fmg020190	+++	-	0
D7	37	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg050244	++	-	3+
D8	38	58	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg010766	+++	+++	0
D9	39	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010824	+++	+	3+
D10	40	55	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIB	malignant	Fmg010908	+	-	3+
E1	41	76	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIB	malignant	Fmg010789	+++	+++	0

E2	42	51	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg010905	++	+	3+
E3	43	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020188	++	-	0
E4	44	50	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIB	malignant	Fmg020304	+++	+++	0
E5	45	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020013	+++	-	0
E6	46	41	F	Breast	Invasive ductal carcinoma	T2N0M0	-	IIA	malignant	Fmg050277	-	-	0
E7	47	44	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	malignant	Fmg010823	-	-	3+
E8	48	47	F	Breast	Invasive ductal carcinoma	T4bN0M0	2	IIIB	malignant	Fmg010950	-	-	3+
E9	49	38	F	Breast	Invasive ductal carcinoma	T1N1M0	-	IIA	malignant	Fmg020137	+++	+++	0
E10	50	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	malignant	Fmg050237	+++	+++	0
F1	51	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010802	+	-	3+
F2	52	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010764	*	*	*
F3	53	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010944	-	-	0
F4	54	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010946	-	-	0
F5	55	38	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg020136	-	-	0
F6	56	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010811	-	-	0
F7	57	40	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	Fmg020194	-	-	0
F8	58	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020175	+	+	*
F9	59	71	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIB	malignant	Fmg020095	+++	+++	0
F10	60	47	F	Breast	Invasive ductal carcinoma	T2N1M0	-	IIB	malignant	Fmg061126	+	-	3+
G1	61	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010931	+++	+++	0
G2	62	35	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	Fmg020094	++	++	3+
G3	63	47	F	Breast	Invasive ductal carcinoma	T4bN0M0	2	IIIB	malignant	Fmg010858	++	+++	3+
G4	64	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010859	++	++	0
G5	65	38	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIA	malignant	Fmg020173	-	-	3+
G6	66	55	F	Breast	Invasive ductal carcinoma	T2N0M0	-	IIA	malignant	Fmg010943	*	*	3+
G7	67	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010920	+++	+	0
G8	68	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010851	++	+	3+
G9	69	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010778	-	-	3+
G10	70	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010826	-	-	0
H1	71	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg050249	+++	-	3+
H2	72	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020090	+++	++	0
H3	73	59	F	Breast	Invasive ductal carcinoma	T4bN0M0	2	IIIB	malignant	Fmg010937	+++	+	0
H4	74	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010860	+++	+++	0
H5	75	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010774	+++	+++	0
H6	76	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020199	-	-	0
H7	77	54	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	Fmg020088	+++	++	3+
H8	78	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010934	++	++	3+
H9	79	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010914	+++	+++	3+
H10	80	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010835	+++	+++	0
I1	81	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg050229	+++	+++	0
I2	82	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020185	+	+++	1+
I3	83	32	F	Breast	Invasive ductal carcinoma	T2N0M0	-	IIA	malignant	Fmg020087	*	*	*
I4	84	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010910	+	+++	0
I5	85	70	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020146	+++	+++	0
I6	86	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg020205	+++	++	3+
I7	87	48	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIIA	malignant	Fmg050234	+++	-	1+
I8	88	44	F	Breast	Invasive ductal carcinoma	T4aN0M0	2	IIIB	malignant	Fmg050282	-	-	2+
I9	89	69	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	malignant	Fmg020184	+++	-	0
I10	90	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010924	+	-	0
J1	91	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010840	+++	+	0
J2	92	42	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIB	malignant	Fmg050720	++	-	0
J3	93	42	F	Breast	Invasive ductal carcinoma	T2N2M0	2	IIIA	malignant	Fmg010821	+++	+++	0
J4	94	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010929	-	-	0
J5	95	68	F	Breast	Invasive ductal carcinoma	T4bN0M0	2	IIIB	malignant	Fmg010927	-	-	3+
J6	96	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010922	+++	+++	0
J7	97	49	F	Breast	Invasive ductal carcinoma	T2N0M0	3	IIA	malignant	Fmg020181	-	-	3+
J8	98	69	F	Breast	Invasive ductal carcinoma	T2N0M0	3	IIA	malignant	Fmg020178	+	-	3+
J9	99	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010933	-	-	0
J10	100	29	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	malignant	Fmg010803	-	-	3+

K1	101	51	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg020326	++	++	0
K2	102	37	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg020550	++	++	0
K3	103	35	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg060379	++	+	0
K4	104	45	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg010231	-	-	0
K5	105	35	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg010800	+	++	0
K6	106	46	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg032110	+	+	0
K7	107	49	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg010251	+	+	0
K8	108	44	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg020543	+	+	0
K9	109	38	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg040763	+	+	0
K10	110	37	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg010802	++	+	0

Supplementary material _1

Journal name: The Romanian Journal of Laboratory Medicine

Article title: High *DNAJA4* expression correlates with poor survival outcomes in breast cancer

TMA Name BR486

Description Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 16 cases/48 cores

Panel Breast invasive ductal carcinoma tissue microarray with matched adjacent normal breast tissue, containing 16 cases of breast invasive ductal carcinoma with matched adjacent normal breast tissue, triplicate cores per case

Cases 16

Cores 48

Diameter 5

Rows 6

Columns 8

- One sample (Positions: A8, B8, C8) is overlap with the case of TMA (BC081116b; Position: D6)

Position	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Tissue ID.
A1	1	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg020311
A2	2	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg020207
A3	3	46	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	Fmg030942
A4	4	51	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	177936
A5	5	39	F	Breast	Invasive ductal carcinoma	T2N1M0	2	Ilb	malignant	179516
A6	6	50	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	179596
A7	7	48	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	Fmg010703
A8	8	34	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	Fmg020190
B1	9	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg020311
B2	10	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg020207
B3	11	46	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	Fmg030942
B4	12	51	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	177936
B5	13	39	F	Breast	Invasive ductal carcinoma	T2N1M0	2	Ilb	malignant	179516
B6	14	50	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	179596
B7	15	48	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	Fmg010703
B8	16	34	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	Fmg020190
C1	17	60	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020311
C2	18	53	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020207
C3	19	46	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg030942
C4	20	51	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	177936
C5	21	39	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	179516
C6	22	50	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	179596
C7	23	48	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg010703
C8	24	34	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020190
D1	25	31	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg010849
D2	26	53	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	180239
D3	27	52	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	Fmg050572
D4	28	50	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	Fmg020446
D5	29	46	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	Fmg020396
D6	30	37	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	Fmg020323
D7	31	46	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	Fmg010907
D8	32	50	F	Breast	Invasive ductal carcinoma	T2N2M0	3	IIIa	malignant	Fmg020458
E1	33	31	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	Fmg010849
E2	34	53	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	180239
E3	35	52	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	Fmg050572
E4	36	50	F	Breast	Invasive ductal carcinoma	T2N1M0	1	Ilb	malignant	Fmg020446
E5	37	46	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	Fmg020396
E6	38	37	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	Fmg020323
E7	39	46	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	Fmg010907
E8	40	50	F	Breast	Invasive ductal carcinoma	T2N2M0	3	IIIa	malignant	Fmg020458
F1	41	31	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg010849
F2	42	53	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	180239
F3	43	52	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg050572
F4	44	50	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020446
F5	45	46	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020396
F6	46	37	F	Breast	Cancer adjacent normal breast tissue -	-	-	-	NAT	Fmg020323

F7	47	46	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg010907
F8	48	50	F	Breast	Cancer adjacent normal breast tissue -	-	-	NAT	Fmg020458

Supplementary material _1**Journal name:** The Romanian Journal of Laboratory Medicine**Article title:** High *DNAJA4* expression correlates with poor survival outcomes in breast cancer

TMA Name BR243z
Description Breast cancer tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6cases/24 cores, replacing BR243y
Panel Breast carcinoma tissue microarray with matched adjacent normal breast tissue, containing 6 cases of breast invasive ductal carcinoma and matched adjacent normal breast tissue, quadruple cores per case
Cases 6
Cores 24
Diameter 5
Rows 3
Columns 8

Position	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Tissue ID.
A1	1	42	F	Breast	Invasive ductal carcinoma	TisNOM0	1		Malignant	Fmg150231
A2	2	42	F	Breast	Invasive ductal carcinoma	TisNOM0	1		Malignant	Fmg150231
A3	3	42	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg150231
A4	4	42	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg150231
A5	5	42	F	Breast	Invasive ductal carcinoma	T2N2M0	2		Malignant	Fmg110063
A6	6	42	F	Breast	Invasive ductal carcinoma	T2N2M0	2		Malignant	Fmg110063
A7	7	42	F	Breast	Cancer adjacent breast tissue -	-	-		AT	Fmg110063
A8	8	42	F	Breast	Cancer adjacent breast tissue -	-	-		AT	Fmg110063
B1	9	53	F	Breast	Invasive ductal carcinoma	T3NOM0	2		Malignant	Fmg140096
B2	10	53	F	Breast	Invasive ductal carcinoma	T3NOM0	2		Malignant	Fmg140096
B3	11	53	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg140096
B4	12	53	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg140096
B5	13	29	F	Breast	Invasive ductal carcinoma	T2N2M0	3		Malignant	Fmg140093
B6	14	29	F	Breast	Invasive ductal carcinoma	T2N2M0	3		Malignant	Fmg140093
B7	15	29	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg140093
B8	16	29	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg140093
C1	17	44	F	Breast	Invasive ductal carcinoma	T2NOM0	2		Malignant	Fmg150436
C2	18	44	F	Breast	Invasive ductal carcinoma	T2NOM0	2		Malignant	Fmg150436
C3	19	44	F	Breast	Cancer adjacent breast tissue -	-	-		AT	Fmg150436
C4	20	44	F	Breast	Cancer adjacent breast tissue -	-	-		AT	Fmg150436
C5	21	34	F	Breast	Invasive ductal carcinoma	T2NOM0	3		Malignant	Fmg110075
C6	22	34	F	Breast	Invasive ductal carcinoma	T2NOM0	3		Malignant	Fmg110075
C7	23	34	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg110075
C8	24	34	F	Breast	Adjacent normal breast tissue -	-	-		NAT	Fmg110075

Supplementary material _1**Journal name:** The Romanian Journal of Laboratory Medicine**Article title:** High *DNAJA4* expression correlates with poor survival outcomes in breast cancer**RNA seq datasets used for the estimation of overall survival**

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and OS) -selected patients	Gene found	No. patients	No. OS
4.3	TCGA	TCGA et al., 2012	743	743	yes	743	95
4.3	SCAN-B / GSE96058	Saal et al., 2015	3 273	3 273	yes	3 273	336
4.3	SCAN-B / GSE81538	Brueffer et al., 2018	405	0	yes	0	0
Total:			4 421	4 016	3	4 016	431

Summary: Targeted prognostic analyses for *DNAJA4* with all nodal status, all ER status and all PR status patients with overall survival (OS) information (n = 4 016).**RNA seq datasets used for the estimation of disease-free survival**

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and DFS) -selected patients	Gene found	No. patients	No. DFS
4.3	TCGA	TCGA et al., 2012	743	743	yes	743	131
4.3	SCAN-B / GSE96058	Saal et al., 2015	3 273	3 273	yes	3 273	336
4.3	SCAN-B / GSE81538	Brueffer et al., 2018	405	0	yes	0	0
Total:			4 421	4 016	3	4 016	467

Summary: Targeted prognostic analyses for *DNAJA4* with all nodal status, all ER status and all PR status patients with disease-free survival (DFS) information (metastatic or any relapse, or death) (n = 4 016).**RNA seq datasets used for the estimation of distant metastasis free survival**

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and DMFS) -selected patients	Gene found	No. patients	No. DMFS
4.4	TCGA	TCGA et al., 2012	743	743	yes	743	41
Total:			743	743	1	743	41

Summary: Targeted prognostic analyses for *DNAJA4* with all nodal status, all ER status and all PR status patients with distant metastasis-free survival (DMFS) information (n = 743).

Supplementary material _1

Journal name: The Romanian Journal of Laboratory Medicine

Article title: High *DNAJA4* expression correlates with poor survival outcomes in breast cancer

DNA Microarray datasets used for the estimation of overall survival

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and OS) -selected patients	Gene found	No. patients	No. OS
1	Rosetta2002	Van de Vijver et al., 2002	295	295	yes	295	79
1	PNAS1732912100	Sotiriou et al., 2003	99	99	no	0	0
1	GSE1379	Ma et al., 2004	59	0	yes	0	0
1	GSE2603	Minn et al., 2005	82	0	yes	0	0
1	GSE1456	Pawitan et al., 2005	159	159	yes	159	40
1	GSE2034	Wang et al., 2005	286	0	yes	0	0
1	GSE2741	Weigelt et al., 2005	50	50	yes	50	10
1	GSE3143	Bild et al., 2006	158	158	no	0	0
1	E_TABM_158	Chin et al., 2006	112	112	yes	112	35
1	GSE4922	Ivshina et al., 2006	249	0	yes	0	0
1	GSE7390	Desmedt et al., 2007	198	198	yes	198	56
1	GSE6532	Loi et al., 2007	267	0	yes	0	0
1	GSE5327	Minn et al., 2007	58	0	yes	0	0
1	E_UCON_1	Naderi et al., 2007	135	135	yes	135	47
1	GSE7849	Anders et al., 2008	75	0	no	0	0
1	GSE9893	Chanrion et al., 2008	151	151	yes	151	41
1	GSE9195	Loi et al., 2008	77	0	yes	0	0
1	GSE10510	Calabrò et al., 2009	139	134	yes	134	63
1	GSE11264	Jézéquel et al., 2009	252	252	no	0	0
1.1	GSE11121	Schmidt et al., 2008	200	0	yes	0	0
1.1	GSE12093	Zhang et al., 2009	136	0	yes	0	0
3.1	GSE8757	Chin et al., 2007	171	171	yes	171	57
3.1	GSE7378	Zhou et al., 2007	54	0	yes	0	0
3.1	GSE16391	Desmedt et al., 2009	55	0	yes	0	0
3.1	GSE22133	Jönsson et al., 2010	346	339	yes	339	151
3.1	GSE19615	Li et al., 2010	115	0	yes	0	0
3.1	GSE17907	Sircoulomb et al., 2010	55	0	yes	0	0
3.1	GSE22219	Buffa et al., 2011	216	0	yes	0	0
3.1	GSE20711	Dedeurwaerder et al., 2011	85	0	yes	0	0
3.1	GSE26971	Filipits et al., 2011	277	0	yes	0	0

3.1	GSE25055	Hatzis et al., 2011	309	0	yes	0	0
3.1	GSE20685	Kao et al., 2011	296	296	yes	296	62
3.1	GSE21653	Sabatier et al., 2011	239	0	yes	0	0
3.1	GSE16987	Wang et al., 2011	149	0	yes	0	0
3.1	GSE33926	Kuo et al., 2012	51	0	yes	0	0
3.1	GSE45255	Nagalla et al., 2013	41	41	yes	41	10
4.3	GSE2109	expO et al., 2005	298	0	yes	0	0
4.3	GSE8193	Yau et al., 2007	47	0	yes	0	0
4.3	GSE20462	Parris et al., 2010	94	94	yes	94	44
4.3	GSE17705	Symmans et al., 2010	43	0	yes	0	0
4.3	GSE24450	Heikkinen et al., 2011	174	174	yes	174	27
4.3	GSE31448	Sabatier et al., 2011	71	0	yes	0	0
4.3	METABRIC	Curtis et al., 2012	1 980	1 980	yes	1 980	1 143
4.3	E_MTAB_365	Guedj et al., 2012	536	0	yes	0	0
4.3	GSE30682	Servant et al., 2012	343	0	yes	0	0
4.3	GSE42568	Clarke et al., 2013	104	104	yes	104	35
4.3	GSE40115	Larsen et al., 2013	183	0	yes	0	0
4.3	GSE55348	Castagnoli et al., 2014	53	0	yes	0	0
4.3	GSE43358	Fumagalli et al., 2014	56	55	yes	55	5
4.3	GSE36295	Merdad et al., 2014	45	0	yes	0	0
4.3	GSE37751	Terunuma et al., 2014	55	55	yes	55	19
4.3	GSE76274	Burstein et al., 2015	66	0	yes	0	0
4.3	GSE97177	Biermann et al., 2017	53	0	yes	0	0
4.6	GSE80999	Aure et al., 2017	381	0	yes	0	0
4.6	GSE86166	Prabhakaran et al., 2017	366	366	yes	366	103
Total:			10 644	5 418	51	4 909	2 027

Summary: Targeted prognostic analyses for DNAJA4 with all nodal status, all ER status and all PR status patients with overall survival (OS) information (n = 4 909).

DNA Microarray datasets used for the estimation of disease-free survival

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and DFS) -selected patients	Gene found	No. patients	No. DFS
1	Rosetta2002	Van de Vijver et al., 2002	295	295	yes	295	122
1	PNAS1732912100	Sotiriou et al., 2003	99	99	no	0	0
1	GSE1379	Ma et al., 2004	59	59	yes	59	27
1	GSE2603	Minn et al., 2005	82	82	yes	82	27
1	GSE1456	Pawitan et al., 2005	159	159	yes	159	50

1	GSE2034	Wang et al., 2005	286	286	yes	286	107
1	GSE2741	Weigelt et al., 2005	50	50	yes	50	13
1	GSE3143	Bild et al., 2006	158	158	no	0	0
1	E_TABM_158	Chin et al., 2006	112	112	yes	112	42
1	GSE4922	Ivshina et al., 2006	249	249	yes	249	89
1	GSE7390	Desmedt et al., 2007	198	198	yes	198	91
1	GSE6532	Loi et al., 2007	267	259	yes	259	88
1	GSE5327	Minn et al., 2007	58	58	yes	58	11
1	E_UCON_1	Naderi et al., 2007	135	135	yes	135	65
1	GSE7849	Anders et al., 2008	75	75	no	0	0
1	GSE9893	Chanrion et al., 2008	151	151	yes	151	55
1	GSE9195	Loi et al., 2008	77	77	yes	77	13
1	GSE10510	Calabrò et al., 2009	139	134	yes	134	96
1	GSE11264	Jézéquel et al., 2009	252	252	no	0	0
1.1	GSE11121	Schmidt et al., 2008	200	200	yes	200	46
1.1	GSE12093	Zhang et al., 2009	136	136	yes	136	20
3.1	GSE8757	Chin et al., 2007	171	171	yes	171	56
3.1	GSE7378	Zhou et al., 2007	54	54	yes	54	9
3.1	GSE16391	Desmedt et al., 2009	55	55	yes	55	55
3.1	GSE22133	Jönsson et al., 2010	346	339	yes	339	151
3.1	GSE19615	Li et al., 2010	115	115	yes	115	14
3.1	GSE17907	Sircoulomb et al., 2010	55	39	yes	39	17
3.1	GSE22219	Buffa et al., 2011	216	216	yes	216	82
3.1	GSE20711	Dedeurwaerder et al., 2011	85	85	yes	85	36
3.1	GSE26971	Filipits et al., 2011	277	258	yes	258	58
3.1	GSE25055	Hatzis et al., 2011	309	309	yes	309	65
3.1	GSE20685	Kao et al., 2011	296	296	yes	296	73
3.1	GSE21653	Sabatier et al., 2011	239	229	yes	229	74
3.1	GSE16987	Wang et al., 2011	149	147	yes	147	10
3.1	GSE33926	Kuo et al., 2012	51	51	yes	51	12
3.1	GSE45255	Nagalla et al., 2013	41	41	yes	41	14
4.3	GSE2109	expO et al., 2005	298	0	yes	0	0
4.3	GSE8193	Yau et al., 2007	47	0	yes	0	0
4.3	GSE20462	Parris et al., 2010	94	94	yes	94	44
4.3	GSE17705	Symmans et al., 2010	43	43	yes	43	8
4.3	GSE24450	Heikkinen et al., 2011	174	174	yes	174	34
4.3	GSE31448	Sabatier et al., 2011	71	0	yes	0	0
4.3	METABRIC	Curtis et al., 2012	1 980	1 980	yes	1 980	1 235
4.3	E_MTAB_365	Guedj et al., 2012	536	526	yes	526	118
4.3	GSE30682	Servant et al., 2012	343	0	yes	0	0

4.3	GSE42568	Clarke et al., 2013	104	104	yes	104	48
4.3	GSE40115	Larsen et al., 2013	183	0	yes	0	0
4.3	GSE55348	Castagnoli et al., 2014	53	53	yes	53	23
4.3	GSE43358	Fumagalli et al., 2014	56	55	yes	55	10
4.3	GSE36295	Merdad et al., 2014	45	0	yes	0	0
4.3	GSE37751	Terunuma et al., 2014	55	55	yes	55	19
4.3	GSE76274	Burstein et al., 2015	66	0	yes	0	0
4.3	GSE97177	Biermann et al., 2017	53	0	yes	0	0
4.6	GSE80999	Aure et al., 2017	381	0	yes	0	0
4.6	GSE86166	Prabhakaran et al., 2017	366	366	yes	366	119
Total:			10 644	9 079	51	8 495	3 346

Summary: Targeted prognostic analyses for DNAJA4 with all nodal status, all ER status and all PR status patients with disease-free survival (DFS) information (metastatic or any relapse, or death) (n = 8 495).

DNA Microarray datasets used for the estimation of distant metastasis free survival

Ver	Study code	Original data		Filtered data		Final data	
		Reference	No. patients	(N all, ER all, PR all and DMFS) -selected patients	Gene found	No. patients	No. DMFS
1	Rosetta2002	Van de Vijver et al., 2002	295	295	yes	295	101
1	PNAS1732912100	Sotiriou et al., 2003	99	99	no	0	0
1	GSE1379	Ma et al., 2004	59	0	yes	0	0
1	GSE2603	Minn et al., 2005	82	82	yes	82	27
1	GSE1456	Pawitan et al., 2005	159	159	yes	159	40
1	GSE2034	Wang et al., 2005	286	286	yes	286	107
1	GSE2741	Weigelt et al., 2005	50	50	yes	50	13
1	GSE3143	Bild et al., 2006	158	0	no	0	0
1	E_TABM_158	Chin et al., 2006	112	112	yes	112	21
1	GSE4922	Ivshina et al., 2006	249	0	yes	0	0
1	GSE7390	Desmedt et al., 2007	198	198	yes	198	62
1	GSE6532	Loi et al., 2007	267	259	yes	259	66
1	GSE5327	Minn et al., 2007	58	58	yes	58	11
1	E_UCON_1	Naderi et al., 2007	135	0	yes	0	0
1	GSE7849	Anders et al., 2008	75	75	no	0	0
1	GSE9893	Chanrion et al., 2008	151	151	yes	151	46
1	GSE9195	Loi et al., 2008	77	77	yes	77	10
1	GSE10510	Calabrò et al., 2009	139	0	yes	0	0
1	GSE11264	Jézéquel et al., 2009	252	252	no	0	0


1.1	GSE11121	Schmidt et al., 2008	200	200	yes	200	46
1.1	GSE12093	Zhang et al., 2009	136	136	yes	136	20
3.1	GSE8757	Chin et al., 2007	171	171	yes	171	38
3.1	GSE7378	Zhou et al., 2007	54	54	yes	54	9
3.1	GSE16391	Desmedt et al., 2009	55	0	yes	0	0
3.1	GSE22133	Jönsson et al., 2010	346	0	yes	0	0
3.1	GSE19615	Li et al., 2010	115	115	yes	115	14
3.1	GSE17907	Sircoulomb et al., 2010	55	39	yes	39	17
3.1	GSE22219	Buffa et al., 2011	216	216	yes	216	82
3.1	GSE20711	Dedeurwaerder et al., 2011	85	0	yes	0	0
3.1	GSE26971	Filipits et al., 2011	277	258	yes	258	58
3.1	GSE25055	Hatzis et al., 2011	309	309	yes	309	65
3.1	GSE20685	Kao et al., 2011	296	296	yes	296	63
3.1	GSE21653	Sabatier et al., 2011	239	0	yes	0	0
3.1	GSE16987	Wang et al., 2011	149	0	yes	0	0
3.1	GSE33926	Kuo et al., 2012	51	51	yes	51	12
3.1	GSE45255	Nagalla et al., 2013	41	41	yes	41	14
4.3	GSE2109	expO et al., 2005	298	0	yes	0	0
4.3	GSE8193	Yau et al., 2007	47	0	yes	0	0
4.3	GSE20462	Parris et al., 2010	94	0	yes	0	0
4.3	GSE17705	Symmans et al., 2010	43	43	yes	43	8
4.3	GSE24450	Heikkinen et al., 2011	174	174	yes	174	34
4.3	GSE31448	Sabatier et al., 2011	71	0	yes	0	0
4.3	METABRIC	Curtis et al., 2012	1 980	1 980	yes	1 980	602
4.3	E_MTAB_365	Guedj et al., 2012	536	526	yes	526	118
4.3	GSE30682	Servant et al., 2012	343	0	yes	0	0
4.3	GSE42568	Clarke et al., 2013	104	0	yes	0	0
4.3	GSE40115	Larsen et al., 2013	183	0	yes	0	0
4.3	GSE55348	Castagnoli et al., 2014	53	0	yes	0	0
4.3	GSE43358	Fumagalli et al., 2014	56	55	yes	55	10
4.3	GSE36295	Merdad et al., 2014	45	0	yes	0	0
4.3	GSE37751	Terunuma et al., 2014	55	0	yes	0	0
4.3	GSE76274	Burstein et al., 2015	66	0	yes	0	0
4.3	GSE97177	Biermann et al., 2017	53	0	yes	0	0
4.6	GSE80999	Aure et al., 2017	381	0	yes	0	0
4.6	GSE86166	Prabhakaran et al., 2017	366	0	yes	0	0
Total:			10 644	6 817	51	6 391	1 714

Summary: Targeted prognostic analyses for DNAJA4 with all nodal status, all ER status and all PR status patients with distant metastasis-free survival (DMFS) information (n = 6 391).


Supplementary material 2

Journal name: The Romanian Journal of Laboratory Medicine

Article title: High *DNAJA4* expression correlates with poor survival outcomes in breast cancer



Supplementary Figure 1. *DNAJA4* expression in clinical breast cancer samples. (A) UALCAN in-silico tool shows that clinical breast cancer samples have significantly higher levels of *DNAJA4* transcripts compared to normal samples (B) Luminal and HER2+ samples have significantly higher levels of *DNAJA4* mRNA compared to normal samples (<http://ualcan.path.uab.edu/>).



Supplementary Figure 2. *c-MYC* mRNA expression in breast cancer subtypes. *c-MYC* mRNA expression is significantly reduced in breast cancer subtypes relative to the normal samples analyzed by UALCAN web-based tool (<http://ualcan.path.uab.edu/>).

Supplementary Table 1. Association of *DNAJA4* protein expression and clinical characteristics of invasive breast carcinoma samples. Staining scores of the samples were grouped as "0" vs "1+2+3". Statistical analyses were performed by GraphPad software using Fisher's exact test with a significance level of $P < 0.05$.

		IHC Score (0) n (%)		IHC Score (1+2+3) n (%)
Tumor stage				
	TI	4 (44)		5 (56)
	TII-TIV	58 (52.25)		53 (47.75)
			P = 0.737	
	TI-TII	46 (47.92)		50 (52.08)
	TIII-TIV	16 (66.67)		8 (33.33)
			P = 0.115	
Lymph node stage				
	N0	50 (51.55)		47 (48.45)
	NI-NII	11 (45.83)		13 (54.16)
			P = 0.654	
Grade				
	GI	7 (41.18)		10 (58.82)
	GII-GIII	51 (52.58)		46 (47.42)
			P = 0.438	
Stage				
	SI	4 (50)		4 (50)
	SII-SIII	56 (52.34)		51 (47.66)
			P > 0.999	
HER2				
	Negative	29 (53.70)		25 (46.30)
	Positive	25 (59.52)		17 (40.48)
			P = 0.679	
PR				
	Negative	29 (59.18)		20 (40.81)
	Positive	24 (51.06)		23 (48.94)
			P = 0.538	
ER				
	Negative	22 (68.75)		10 (31.25)
	Positive	31 (48.44)		33 (51.56)
			P = 0.082	